New clinical trial data released by Eli Lilly on Wednesday has provided the most promising results of any potential Alzheimer’s disease treatment yet. In a randomized, double-blinded, controlled phase III trial, the experimental drug donanemab significantly slowed cognitive decline in patients compared to placebo,…
